Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Red Cells and Iron
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594003/
https://ncbi.nlm.nih.gov/pubmed/30768680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15790
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados